Concord Biotech Limited
ListedMainboardPharmaceuticals & Biotechnology · NSE / BSE
Incorporated in 1984, Concord Biotech Limited is an India-based biopharmaceutical company and a leading global developer and manufacturer of fermentation-based APIs, specializing in immunosuppressants and oncology. The company has a strong global presence, supplying products to over 70 countries including the USA, India, Europe, and Japan. Concord Biotech manufactures Active Pharmaceutical Ingredients (APIs) through fermentation and semi-synthetic processes, along with finished formulations. Starting with a single product, the company has expanded to offer a broad spectrum of biopharma solutions, establishing itself as a key player in the global API market.
Price Band
₹705 – ₹741
Issue Size
₹1551 Cr
Lot Size
20 shares
GMP
₹125
+16.9%
Est. Listing
₹866
at current GMP
Subscribed
26.13x
overall
Open
4 Aug 2023
Close
8 Aug 2023
Allotment
14 Aug 2023
Refund
15 Aug 2023
Demat Credit
16 Aug 2023
Listing
18 Aug 2023
Last updated 12 days ago
Official Registrar Verification
Concord Biotech Limited Allotment Status
Designated Registrar: Link Intime India Private Limited
Allotment Date
14 Aug 2023
Basis finalization
Refunds Initiate
15 Aug 2023
Mandate release
Demat Credit
16 Aug 2023
Shares in demat
Listing Debut
18 Aug 2023
Trading begins
How to Check Concord Biotech Limited IPO Allotment Status
- Click the Check on Registrar button above to visit Link Intime India Private Limited's allotment portal.
- Select Concord Biotech Limited from the dropdown company list.
- Choose your lookup mode: PAN Number, Application Number, or DP Client ID.
- Enter your details accurately and solve the Captcha code.
- Click Submit / Search to view the number of shares applied and allotted to you.
About Concord Biotech Limited Public Issue & Market Profile
Concord Biotech Limited is bringing an initial public offering (IPO) in the Pharmaceuticals & Biotechnology sector with an aggregate issue size of ₹1,551 Crores. The shares are offered at a price band of ₹705 to ₹741 per equity share on NSE and BSE. Currently, market analysts recommend evaluating the company's financial valuation, price-to-earnings (P/E) multiple, and peer comparison prior to submitting bids.
Public Issue & Allotment Procedure:
The public offer consists of a fresh issue and offer-for-sale structured under SEBI regulations. Bidding is open to Qualified Institutional Buyers (QIB), Non-Institutional Bidders (NII/HNI), and Retail Individual Investors (RII). Applications can be submitted online using ASBA or UPI mandate through certified stock brokers and net banking portals.
Official Allotment Timelines & Registrar Guidance:
Following the close of bidding on 2023-08-08, the basis of allotment is scheduled to be finalized on 2023-08-14. Investors can verify their application status online by submitting their PAN card number, Application Number, or DP Client ID on the registrar's official portal (Link Intime India Private Limited) or the BSE allotment checking window.
Frequently Asked Questions
What if my name is not showing on the registrar portal?
Allotment records are updated in batches. If the status is not yet available, please wait a few hours until the basis of allotment is fully finalized.
How will I receive the refund if I don't get allotment?
Since funds are blocked under ASBA/UPI, the bank will automatically release the blocked hold on your funds upon receipt of revocation instructions from the sponsor bank.